secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0000950170-22-010067
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Q1 revenue $168M (+282% YoY); raises FY22 total revenue guidance to $375-390M
--------------------------------------------------------------------------------

- Total revenue $168M (+282% YoY); Foundry revenue $21M (-5% YoY); Biosecurity revenue $147M.
- Loss from operations $(675)M incl. $659M stock comp; Adj. EBITDA $(2)M improved from $(51)M.
- Added 11 new Cell Programs in Q1; FY22 target of 60 new programs unchanged.
- Raised FY22 total revenue guidance to $375-390M from $325-340M; Foundry guidance unchanged.
- Announced plans to acquire Bayer's West Sacramento ag biologics site and flagship collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000095017022010067/0000950170-22-010067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000095017022010067/dna-20220516.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-010067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer